{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:51:20Z","timestamp":1770994280157,"version":"3.50.1"},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T00:00:00Z","timestamp":1350604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Forensic Sciences"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This case report describes a 34\u2010year\u2010old male who died as the result of tapentadol toxicity. This case apparently represents the first reported description of a death because of this drug. The toxicologic features of this case, namely concentrations of tapentadol in the femoral blood and heart blood, 1.05 and 3.20\u00a0mg\/L, respectively, may assist other individuals in evaluating deaths where tapentadol concentration is a factor. Analysis of the blood based upon enzyme\u2010linked immunosorbent assays, liquid chromatography\u2013mass spectrometry, and gas chromatography\u2013mass spectrometry revealed no other substance of significance, only nicotine and cotinine, and the autopsy findings were consistent with an opiate\u2010type drug overdose, and indicated no competing cause of death.<\/jats:p>","DOI":"10.1111\/j.1556-4029.2012.02299.x","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T18:56:17Z","timestamp":1350672977000},"page":"288-291","source":"Crossref","is-referenced-by-count":26,"title":["Death Due to Apparent Intravenous Injection of Tapentadol"],"prefix":"10.1111","volume":"58","author":[{"given":"Walter","family":"Kemp","sequence":"first","affiliation":[{"name":"Montana State Forensic Science Division P.O. Box 16010 Missoula MT 59808"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Schlueter","sequence":"additional","affiliation":[{"name":"Montana State Forensic Science Division P.O. Box 16010 Missoula MT 59808"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Smalley","sequence":"additional","affiliation":[{"name":"Montana State Forensic Science Division P.O. Box 16010 Missoula MT 59808"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,19]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.12.003"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2010.02.006"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aer126"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2009.833"},{"issue":"10","key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5414\/CPP48678","article-title":"A thorough QT\/QTc study of multiple doses of tapentadol immediate release in healthy subjects","volume":"48","author":"Oh C","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_5_7_1","volume-title":"Nucynta [package insert]","author":"Ortho\u2010McNeil\u2010Janssen Pharmaceuticals, Inc","year":"2008"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190478"},{"key":"e_1_2_5_9_1","unstructured":"Therapeutic Goods Administration Department of Health and Aging Australian Government.Australian public assessment report for tapentadol: Feb 2011.Therapeutic Goods Administration. AusPar Palexia IR Tapentadol CSL Pty Ltd PM\u20102009\u201002488\u20103\u20101."},{"key":"e_1_2_5_10_1","first-page":"487","volume-title":"Forensic pathology: principles and practice","author":"Dolinak D","year":"2005"}],"container-title":["Journal of Forensic Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1556-4029.2012.02299.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1556-4029.2012.02299.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:35:13Z","timestamp":1697387713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1556-4029.2012.02299.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,19]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1556-4029.2012.02299.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1556-4029.2012.02299.x","archive":["Portico"],"relation":{},"ISSN":["0022-1198","1556-4029"],"issn-type":[{"value":"0022-1198","type":"print"},{"value":"1556-4029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,19]]}}}